Filter your results
- 2
- 1
- 3
- 3
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathologyHuman Molecular Genetics, 2010, 19 (16), pp.3138-3149. ⟨10.1093/hmg/ddq222⟩
Journal articles
pasteur-03277064v1
|
||
|
Autoantibodies against type I IFNs in patients with life-threatening COVID-19Science, 2020, 370 (6515), pp.eabd4585. ⟨10.1126/science.abd4585⟩
Journal articles
pasteur-02958871v1
|
||
|
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesProceedings of the National Academy of Sciences of the United States of America, 2022, 119 (21), pp.349-363. ⟨10.1073/pnas.2200413119⟩
Journal articles
hal-03856619v2
|